Clinical Care Guidelines for:
Major Depression in Adults

OBJECTIVE
Guide the appropriate diagnosis and treatment of Major Depression in adults.

DIAGNOSIS & ASSESSMENT

DSM-5 DIAGNOSTIC CRITERIA
Five (5) or more symptoms present during a two (2) week period; (1) depressed mood or (2) loss of interest or pleasure and any three of the following:
• Significant weight loss or decrease in appetite
• Insomnia or hypersomnia
• Psychomotor agitation or retardation
• Fatigue or lack of energy
• Feelings of worthlessness or guilt
• Decreased concentration or indecisiveness
• Recurrent thoughts of death or suicide
Symptoms cause significant distress or impairment in functioning and not due to significant loss or change in life, absence of manic/hypomanic episodes.
The PHQ9 is recommended for screening and treatment monitoring.

RULE OUT/MONITOR CO-OCCURRING MEDICAL CONDITIONS
• Ensure that a general medical evaluation has been completed
• Evaluate functional impairment and quality of life
• Assess level of self-care (nutrition, hydration, ADLs)
• Establish the least restrictive environment for treatment and evaluate frequently for any need to change the level of care
• Assess for Suicidal Ideation/Crisis
  o If the patient has a plan, the means or has recently attempted, hospitalize
  o If the situation is unclear and the patient is being evaluated by a medical provider, refer to a behavioral health practitioner
  o Evaluate level of impulsivity and if patient can commit to not harming himself/herself; seek help if the ideation becomes overwhelming
  o Refer to a psychiatrist or behavioral health professional if symptoms are severe, there are co-morbid conditions, there are significant psychosocial stressors, and/or substance abuse

TREATMENT

MEDICATION MANAGEMENT
If symptoms are moderate to severe, evaluate for medication. If medication is prescribed, patient should be seen within 1–4 weeks to assess and adjust.
At least 12 weeks continuous treatment in the acute phase.
At least one additional visit after the 4 week check in the next 4–8 weeks.
For effective treatment during the continuation phase, monitor medication for the next 6 months. Visits may be less frequent.
To prevent relapse after symptom remission, stay on medication an additional 6–12 months.
Maintenance (greater than 9 months) for patients with a history of chronic symptoms, 3 or more episodes of depression, severe episodes, episodes beginning prior to age 20, or family history of bipolar disorder. Monitor at regular intervals and assess for re-emergence of symptoms. Medication may be required for an additional 15-28 months.
If discontinuing medication, taper slowly over several weeks and monitor for recurrence of symptoms.
Coordinate care with other clinicians involved in care.
Provide education to the family and patient.

PSYCHOTHERAPY
Cognitive behavioral therapy or individual interpersonal therapy–outpatient.
Therapy alone may be used to treat for mild to moderate symptoms.
Frequency depends on the severity of the illness.
For moderate to severe symptoms, therapy should be used in combination with medication.
Regular exercise and education regarding depression are recommended as adjuncts to treatment.
Severe symptoms, decline in functioning and/or suicidal ideation/intent may require a higher level of care.
If patient is discharged from inpatient hospitalization, patient needs to be seen in an outpatient setting, intensive outpatient setting or partial hospitalization by a behavioral health provider within 7 calendar days.
As depression symptoms remit, less frequent therapy sessions would be appropriate to maintain stability.
ECT is appropriate for severe depression that hasn’t responded to numerous medications and/or therapy and patients who have significant functional impairment.

Continued on next page
Antidepressant medications are grouped into the following classes:

1. Tricyclic Antidepressants (TCAs)
2. Select Serotonin Reuptake Inhibitors (SSRIs)
3. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
4. Atypical Antidepressants
5. Monoamine Oxidase Inhibitors (MAOIs)
6. Norepinephrine Reuptake Inhibitor (NRI)
7. Dopamine Agonist (DA)

The effectiveness of antidepressant medications is generally comparable between classes and within classes of medications. Response rates typically range from 50% to 75% among all classes and agents. Antidepressants do differ in their potential to cause particular side effects such as adverse sexual effects, sedation, or weight gain. Because of this, the initial selection of an antidepressant medication regimen should strongly consider the tolerability, safety, and cost of the medication, as well as patient preference and history of prior medication treatment. Second-generation antidepressants, which include the SSRI, SNRI and Atypical Antidepressant classes are optimal and usually preferred for most patients over the older medications in the TCA and MAOI classes.

Antidepressant medication therapy is not a cure for depression. These drugs are effective in treating some of the symptoms of depression, but cannot change underlying contributions to depression in patients’ lives. Studies have shown, and many experts believe, that antidepressant medications often work best in combination with psychotherapy lasting for several months. On their own, antidepressant medications are important, especially in treating patients who have difficulty, or are hesitant in, accessing a psychotherapy professional.

When initiating an antidepressant drug regimen, encourage the patient to be patient as it may take 4-8 weeks for the drug therapy to be fully effective. In addition, side effects may appear in the beginning, but most improve over time. Follow up visits are important to assess treatment response. Finally, consider changes in the drug regimen if significant improvement in symptoms does not occur after six weeks.

First Line Treatment: SSRI, TCA, SNRI, NRI, DA

Second Line Treatment: Switch to a different antidepressant in the same class; switch to an antidepressant of a different class; addition of atypical anti-psychotic

### Medication Therapy Options for Depression

<table>
<thead>
<tr>
<th>Therapeutic Class/ Brand Name</th>
<th>Dosage Forms</th>
<th>Recommended Starting Dose</th>
<th>FDA Maximum Daily Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective Serotonin Reuptake Inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CELEXA® (generic) citalopram</td>
<td>10, 20, 40 mg tablet 10 mg/5ml solution</td>
<td>20mg once daily</td>
<td>40mg</td>
<td>Additive QTc prolongation 2-week washout period between MAOI and SSRI</td>
</tr>
<tr>
<td>LUVOX® (generic) fluvoxamine</td>
<td>25, 50, 100 mg tablet</td>
<td>50mg once daily</td>
<td>300mg</td>
<td>FDA indicated in OCD (off-label use for depression) 2-week washout period between MAOI and SSRI</td>
</tr>
<tr>
<td>LUVOX CR® (generic) fluvoxamine</td>
<td>100, 150 mg capsule</td>
<td>100mg once daily</td>
<td>300mg</td>
<td></td>
</tr>
<tr>
<td>PAXIL/PAXIL CR® (generic) paroxetine</td>
<td>10, 20, 30, 40 mg tablet 10mg/5ml solution 12.5, 25, 37.5 mg ER tablet</td>
<td>20mg once daily (tablet) 25mg once daily (ER tablet)</td>
<td>50mg (tablet) 62.5mg (ER tablet)</td>
<td>Avoid use in pregnancy due to CV effects (all other SSRIs or TCA preferred in pregnancy) 2-week washout period between MAOI and SSRI</td>
</tr>
<tr>
<td>PROZAC® (generic) fluoxetine</td>
<td>10, 20 mg tablet 10, 20, 40 mg capsule 20mg/5ml solution</td>
<td>20mg once daily</td>
<td>80mg</td>
<td>Long half-life = self-tapering (all other antidepressants need to be tapered over several weeks) Activating; take in the morning 5-week wash-out period if switching from fluoxetine to MAOI 2-week washout from MAOI to SSRI</td>
</tr>
<tr>
<td>PROZAC WEEKLY® (generic) fluoxetine</td>
<td>90mg delayed release capsule</td>
<td>90mg once weekly</td>
<td>90mg weekly</td>
<td></td>
</tr>
</tbody>
</table>

Continued on next page
<table>
<thead>
<tr>
<th>Therapeutic Class/ Brand Name</th>
<th>Dosage Forms</th>
<th>Recommended Starting Dose</th>
<th>FDA Maximum Daily Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZOLOFT® (generic) sertraline</td>
<td>25, 50, 100 mg tablet 20mg/ml concentrate</td>
<td>50mg once daily</td>
<td>200mg</td>
<td>First-choice for patients with comorbid CAD 2-week washout period between MAOI and SSRI</td>
</tr>
<tr>
<td>LEXAPRO® (generic) escitalopram</td>
<td>5, 10, 20 mg tablet 5mg/5ml solution</td>
<td>10mg once daily</td>
<td>20mg</td>
<td>Additive QTc prolongation 2-week washout period between MAOI and SSRI</td>
</tr>
<tr>
<td>VIIBRYD® Vilazodone</td>
<td>10, 20, 40 mg tablet</td>
<td>10mg once daily</td>
<td>40mg</td>
<td>Take with food Less sexual side effects 2-week washout period between MAOI and SSRI</td>
</tr>
</tbody>
</table>

Serotonin and Norepinephrine Reuptake Inhibitors

| EFFEXOR/EFFEXOR XR® (generic) venlafaxine | 25, 37.5, 50, 75, 100 mg tablet 37.5, 75, 150 225 mg ER tablet 37.5, 75, 150 mg ER capsule | 37.5mg BID-TID (IR) 37.5mg once daily (ER) | 375mg (tablet) 225mg (ER) | Additive QTc prolongation Highest risk increasing BP, especially at doses > 150 mg/day (all SNRIs have dose-dependent risk) 7-day washout period from SNRI to MAOI; 2-week washout from MAOI to SNRI |
| FETZIMA® levomilnacipran | 20, 40, 80, 120 mg ER capsules | 20 mg once daily | 120 mg | Take capsule whole, do not crush/chew 7-day washout period from SNRI to MAOI; 2-week washout from MAOI to SNRI |
| PRISTIQ® desvenlafaxine | 50, 100 mg ER tablet | 50mg once daily | 200mg | Additive QTc prolongation 7-day washout period from SNRI to MAOI; 2-week washout from MAOI to SNRI |
| CYMBALTA® duloxetine | 20, 30, 60 mg capsule | 20mg BID | 120 mg | Indicated for both depression and neuropathic/musculoskeletal pain 5 to 14-day washout period from SNRI to MAOI; 2-week washout from MAOI to SNRI |

Atypical Antidepressants

<p>| WELLBUTRIN® WELLBUTRIN SR® WELLBUTRIN XL® FORFIVO XL APLENZIN (generic) bupropion | 75, 100 mg tablets 100, 150, 200 mg SR tablets 150, 300 mg XL tablets 174, 348, 522mg tablets (Aplenzin) | 100mg BID (IR) 150mg once daily (SR and XL) 174mg once daily (Aplenzin) | 450mg (IR) 400mg (SR) 450mg (XL) 522mg (Aplenzin) | Least likely to cause weight gain/metabolic abnormalities Less likely to cause sexual side effects High risk of seizures ≥ 450 mg/day 2-week washout period between MAOI and bupropion |
| trazodone HCl (generic) | 50, 100, 150, 300 mg tablets | 50mg BID (IR) | 400mg (IR) | Significant sedation and weight gain Risk of priapism 2-week washout period between MAOI and trazodone |
| REMERON®/REMERON SOLUTAB® (generic) mirtazapine | 7.5, 15, 30, 45 mg tablets | 15mg once daily | 45mg | Significant sedation and weight gain 2-week washout period between MAOI and mirtazapine |</p>
<table>
<thead>
<tr>
<th>Therapeutic Class/ Brand Name</th>
<th>Dosage Forms</th>
<th>Recommended Starting Dose</th>
<th>FDA Maximum Daily Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>nefazodone HCl (generic)</td>
<td>50, 100, 150, 200, 250 mg tablets</td>
<td>100mg BID</td>
<td>Not available. Doses up to 600mg have been used.</td>
<td>High risk of hepatotoxicity 2-week washout period between MAOI and nefazodone</td>
</tr>
<tr>
<td>TRINTELLIX® vortioxetine</td>
<td>5, 10, 20 mg tablets</td>
<td>10mg once daily</td>
<td>20 mg</td>
<td>21-day washout from vortioxetine to MAOI; 2-week washout from MAOI to vortioxetine</td>
</tr>
</tbody>
</table>

Disclaimer: Recommendation of treatment does not guarantee coverage of services.

REFERENCES


Approved by MAC: 8/1/18   Revised: 3/15/16   Reviewed: 03/2020   APP0146 (7/20)